Therapeutic glucocorticoids prevent bone loss but drive muscle wasting when administered in chronic polyarthritis

Autor: C. G. Fenton, J. M. Webster, C. S. Martin, S. Fareed, C. Wehmeyer, H. Mackie, R. Jones, A. P. Seabright, J. W. Lewis, Y. C. Lai, C. S. Goodyear, S. W Jones, M. S. Cooper, G. G. Lavery, R. Langen, K. Raza, R. S. Hardy

Publikováno v: Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-12 (2019)

Abstract Background Patients with rheumatoid arthritis (RA) experience extra-articular manifestations including osteoporosis and muscle wasting, which closely associate with severity of disease. Whilst therapeutic glucocorticoids (GCs) reduce inflamm

Externí odkaz: https://doaj.org/article/88f4fa171f8c489ca2601cae7a73bbe6

Position statement on radiopharmaceutical production for clinical trials

Autor: M. S. Cooper, M. Desruet, R. Schiavo, Arturo Chiti, Vijay Kumar, Sally W. Schwarz, Albert D. Windhorst, Y. Liu, Iván Peñuelas, A. Buck, J. Croasdale, Guy Bormans, C. Rossetti

Publikováno v: Bormans, G, Buck, A, Chiti, A, Cooper, M, Croasdale, J, Desruet, M, Kumar, V, Liu, Y, Penuelas, I, Rossetti, C, Schiavo, R, Schwarz, S W & Windhorst, A D 2017, ' Position statement on radiopharmaceutical production for clinical trials ', EJNMMI radiopharmacy and chemistry, vol. 2, no. 1, pp. 12 . https://doi.org/10.1186/s41181-017-0031-y
Ejnmmi Radiopharmacy and Chemistry
EJNMMI radiopharmacy and chemistry, 2(1). Springer Science and Business Media Deutschland GmbH
EJNMMI Radiopharmacy and Chemistry, Vol 2, Iss 1, Pp 1-3 (2017)

The EU regulation 536/2014 aims to facilitate the experimental use of diagnostic radiopharmaceuticals in particular for GMP requirements and needs to be applied in EU countries. As definitely clarified by this survey, the application is still far fro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::857b028200a3641582252176489cb812
https://research.vumc.nl/en/publications/84ac3156-00c5-4690-818e-2133002344c7

Anaesthetic training: not better, not worse, just different

Autor: A. E. Cooper, C. M. S. Cooper

Publikováno v: Anaesthesia. 67:937-941

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fd111325cbf82462c0d8fa75dbe1539a
https://doi.org/10.1111/j.1365-2044.2012.07262.x

Toxicity of high-activity 111In-Octreotide therapy in patients with disseminated neuroendocrine tumours

Autor: P. L. Croasdale, A.J.W. Hilson, Andrew K. Burroughs, John R. Buscombe, W. Mielcarek, Martyn Caplin, A. L. Jones, M. S. Cooper

Publikováno v: Nuclear Medicine Communications. 21:97-102

Disseminated neuroendocrine tumours are difficult to treat and are generally not responsive to radiotherapy or chemotherapy. Nuclear medicine techniques using a radiolabelled somatostatin analogue, 111In-Octreotide, have been used for the diagnosis o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cb8bb95879444e1b211d468cba12a14
https://doi.org/10.1097/00006231-200001000-00016

Reliability of Low Glass Transition Temperature COTS PEM’s for Space Applications

Autor: M. Sandor, S. Agarwal, D. Peters, M. S. Cooper

Publikováno v: 2003 International Electronic Packaging Technical Conference and Exhibition, Volume 1.

Microcircuit manufacturers of Plastic Encapsulated Microcircuits (PEM’s) have made changes in epoxy molding compound materials and chemistry, which lower Glass Transition Temperature (Tg). PEM users in harsh environments have concerns if either the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b2a0767943ee1b4da38cb859cfa4323b
https://doi.org/10.1115/ipack2003-35177